- Home
- USCB vs NPCE Comparison
USCB vs NPCE Comparison
Compare USCB & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USCB
- NPCE
- Stock Information
- Founded
- USCB 2002
- NPCE 1997
- Country
- USCB United States
- NPCE United States
- Employees
- USCB N/A
- NPCE N/A
- Industry
- USCB Major Banks
- NPCE Medical Specialities
- Sector
- USCB Finance
- NPCE Health Care
- Exchange
- USCB Nasdaq
- NPCE Nasdaq
- Market Cap
- USCB 316.4M
- NPCE 292.9M
- IPO Year
- USCB 2021
- NPCE 2021
- Fundamental
- Price
- USCB $17.34
- NPCE $9.15
- Analyst Decision
- USCB Buy
- NPCE Strong Buy
- Analyst Count
- USCB 3
- NPCE 6
- Target Price
- USCB $20.33
- NPCE $16.67
- AVG Volume (30 Days)
- USCB 16.8K
- NPCE 205.3K
- Earning Date
- USCB 07-24-2025
- NPCE 08-12-2025
- Dividend Yield
- USCB 2.30%
- NPCE N/A
- EPS Growth
- USCB 67.08
- NPCE N/A
- EPS
- USCB 1.47
- NPCE N/A
- Revenue
- USCB $88,094,000.00
- NPCE $88,570,000.00
- Revenue This Year
- USCB $26.38
- NPCE $22.13
- Revenue Next Year
- USCB $4.39
- NPCE $6.07
- P/E Ratio
- USCB $11.83
- NPCE N/A
- Revenue Growth
- USCB 32.06
- NPCE 23.32
- 52 Week Low
- USCB $13.85
- NPCE $5.45
- 52 Week High
- USCB $21.86
- NPCE $18.98
- Technical
- Relative Strength Index (RSI)
- USCB 55.15
- NPCE 51.74
- Support Level
- USCB $17.10
- NPCE $8.61
- Resistance Level
- USCB $17.98
- NPCE $8.99
- Average True Range (ATR)
- USCB 0.52
- NPCE 0.53
- MACD
- USCB 0.06
- NPCE 0.11
- Stochastic Oscillator
- USCB 73.38
- NPCE 75.00
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.